Back to Trials
NCT07456696PHASE3Recruiting

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)

Transcend Therapeutics

Start Date

4/2/2026

Completion Date

12/1/2027

Summary

This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Meets the DSM-5 criteria for current PTSD diagnosis, with a symptom duration of at least 6 months. * Tried at least one pharmacological treatment for PTSD or trauma-focused psychotherapy. * Proficient in communication (verbal and reading) to complete interviews and written questionnaires. * Free from any other clinically significant illness or disease. Exclusion Criteria: * Primary diagnosis of any other DSM-5 disorder. * Body mass index (BMI) \<18 kg/m2 or ≥40 kg/m2. * Unable to refrain from nicotine use for at least 8 hours. * Use of prohibited concomitant medications or therapies. * Current or previous history of clinically significant cardiovascular (including current uncontrolled hypertension) / cerebrovascular conditions.

Interventions

DRUG

TSND-201

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Post Traumatic Stress Disorder

Locations

Del Sol Research

Tucson, Arizona 85715

United States

Preferred Research Partners

Little Rock, Arkansas 72211

United States

Kadima Neuropsychiatry

La Jolla, California 92037

United States

CalNeuro Research Group

Los Angeles, California 90025

United States

Catalina Research Institute

Montclair, California 91763

United States

Excell Research

Oceanside, California 92056

United States

ATP Clinical Research

Orange, California 92866

United States

Inland Psychiatric Medical Group

San Juan Capistrano, California 92675

United States

Starlight Clinical Research

Evergreen, Colorado 80439

United States

CNS Healthcare

Jacksonville, Florida 32256

United States

Segal Trials

Lauderhill, Florida 33319

United States

Accel Clinical Research

Maitland, Florida 32751

United States

CNS Healthcare

Orlando, Florida 32801

United States

Uptown Research Institute

Chicago, Illinois 60640

United States

DelRicht - New Orleans

New Orleans, Louisiana 70115

United States

Headlands Research - Pharmasite

Pikesville, Maryland 21208

United States

Vitalix Clinical

Worcester, Massachusetts 01608

United States

Arch Clinical Trials

Creve Coeur, Missouri 63141

United States

Midwest Research Group

Saint Charles, Missouri 63304

United States

Center for Emotional Fitness/ Lumina Clinical Research Center

Cherry Hill, New Jersey 08002

United States

Global Medical Institutes

Princeton, New Jersey 08540

United States

Bio Behavioral Health

Toms River, New Jersey 08755

United States

Medical Research Network

New York, New York 10128

United States

Insight Clinical Trials

Independence, Ohio 44131

United States

Flourish Research

Plymouth Meeting, Pennsylvania 19462

United States

Suburban Research Associates

West Chester, Pennsylvania 19380

United States

Austin Clinical Trial Partners

Austin, Texas 78737

United States

Haracec Clinical Research

El Paso, Texas 79902

United States

Elevate Clinical Research

Houston, Texas 77058

United States

Cedar Clinical Research

Draper, Utah 84020

United States

Inner Space Research

Orem, Utah 84058

United States

Seattle Neuropsychiatric Treatment Center (NTC)

Seattle, Washington 98104

United States